# Korro Bio, Inc.: overview KRRO · Nasdaq · CIK 1703647 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/krro.md) · [Financials](/companies/krro/financials.md) · [Filings](/companies/krro/filings.md) · [Insiders](/companies/krro/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-336707.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-336707). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001193125-25-277572.md) | [2.3 d](/filings/0001193125-26-104156.md) | [2.6](/filings/0001193125-26-210303.md) | [1.5](/filings/0001193125-26-336707.md) | [1.1](/filings/0001193125-25-277572.md) | [1.3 d](/filings/0001193125-26-104156.md) | [0.0](/filings/0001193125-26-210303.md) | [0.0](/filings/0001193125-26-336707.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(1014.5%) d](/filings/0001193125-26-104156.md) | [(981.2%)](/filings/0001193125-26-210303.md) | [(1863.2%)](/filings/0001193125-26-336707.md) | [(1764.9%)](/filings/0001193125-25-277572.md) | [(3900.6%) d](/filings/0001193125-26-104156.md) | not reported | not reported | | Net margin | % | not reported | [(933.5%) d](/filings/0001193125-26-104156.md) | [(917.1%)](/filings/0001193125-26-336707.md) | [(1765.1%)](/filings/0001193125-26-336707.md) | [(1657.0%)](/filings/0001193125-25-277572.md) | [(3873.2%) d](/filings/0001193125-26-104156.md) | not reported | not reported | | Diluted EPS | $ per share | [(2.26)](/filings/0001193125-25-277572.md) | not reported | [(2.49)](/filings/0001193125-26-210303.md) | [(2.74)](/filings/0001193125-26-336707.md) | [(1.92)](/filings/0001193125-25-277572.md) | not reported | [(1.69)](/filings/0001193125-26-210303.md) | [(1.07)](/filings/0001193125-26-336707.md) | | Free cash flow | $m | [(21.0) d](/filings/0001193125-25-277572.md) | [(8.9) d](/filings/0001193125-26-104156.md) | [(24.6)](/filings/0001193125-26-210303.md) | [(19.4) d](/filings/0001193125-26-336707.md) | [(17.4) d](/filings/0001193125-25-277572.md) | [(17.8) d](/filings/0001193125-26-104156.md) | [(16.1)](/filings/0001193125-26-210303.md) | [(17.0) d](/filings/0001193125-26-336707.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [14.1](/filings/0000950170-23-007140.md) | [0.0](/filings/0000950170-23-007140.md) | [0.0](/filings/0000950170-25-040759.md) | [2.3](/filings/0001193125-26-104156.md) | [6.4](/filings/0001193125-26-104156.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(597.3%)](/filings/0000950170-23-007140.md) | not reported | not reported | [(4047.1%)](/filings/0001193125-26-104156.md) | [(1906.4%)](/filings/0001193125-26-104156.md) | | Net margin | % | [(602.0%)](/filings/0000950170-23-007140.md) | not reported | not reported | [(3680.4%)](/filings/0001193125-26-104156.md) | [(1834.5%)](/filings/0001193125-26-104156.md) | | Diluted EPS | $ per share | [(2.47)](/filings/0000950170-22-003655.md) | [(227.42)](/filings/0000950170-24-036396.md) | [(53.08)](/filings/0000950170-25-040759.md) | [(9.37)](/filings/0001193125-26-104156.md) | [(12.48)](/filings/0001193125-26-104156.md) | | Free cash flow | $m | [(79.0)](/filings/0000950170-23-007140.md) | [(58.8)](/filings/0000950170-24-036396.md) | [(75.1)](/filings/0000950170-25-040759.md) | [(78.0)](/filings/0001193125-26-104156.md) | [(79.1)](/filings/0001193125-26-104156.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/krro/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-10-26 | [Lynx1 Capital Management LP](/insiders/1910456.md) | 10% owner | Purchase (P) | 25,124 | $11.7454 | $295.1k | [Form 4](/filings/0000902664-26-004286.md) | | 2026-10-23 | [Lynx1 Capital Management LP](/insiders/1910456.md) | 10% owner | Purchase (P) | 2,510 | $12.1061 | $30.4k | [Form 4](/filings/0000902664-26-004286.md) | | 2026-10-22 | [Lynx1 Capital Management LP](/insiders/1910456.md) | 10% owner | Purchase (P) | 40,000 | $11.0366 | $441.5k | [Form 4](/filings/0000902664-26-004286.md) | | 2026-10-22 | [Lynx1 Capital Management LP](/insiders/1910456.md) | 10% owner | Purchase (P) | 12,175 | $9.6764 | $117.8k | [Form 4](/filings/0000902664-26-004286.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Lynx1 Capital Management LP](/funds/1910456.md) | 2026-06-30 | $20.3m | 1,538,296 | | Unchanged | | [NEA Management Company, LLC](/funds/1512848.md) | 2026-06-30 | $17.1m | 1,297,893 | | Unchanged | | [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $13.3m | 1,009,500 | | Unchanged | | [Atlas Venture Life Science Advisors, LLC](/funds/1917529.md) | 2026-06-30 | $12.7m | 962,884 | | Reduced −174,265 | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $12.5m | 951,783 | | Reduced −88,271 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $10.8m | 817,621 | | Added +357,615 | | [Affinity Asset Advisors, LLC](/funds/1773195.md) | 2026-06-30 | $9.3m | 706,904 | | Unchanged | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $8.7m | 660,036 | | Unchanged | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $8.7m | 660,036 | | Unchanged | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $7.1m | 540,968 | | Added +312,568 | ## Recent filings [All 821 filings](/companies/krro/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 07:04 ET | [8-K](/filings/0001193125-26-428306.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-428306 | | 2026-10-05 | 16:10 ET | [8-K](/filings/0001193125-26-414118.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-414118 | | 2026-08-19 | 16:05 ET | [8-K](/filings/0001193125-26-356877.md) | 8.01 Other events | 0001193125-26-356877 | | 2026-08-06 | 07:08 ET | [10-Q](/filings/0001193125-26-336707.md) | Quarterly report, period 2026-06-30 | 0001193125-26-336707 | | 2026-08-06 | 07:04 ET | [8-K](/filings/0001193125-26-336685.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-336685 | | 2026-08-04 | 17:13 ET | [SCHEDULE 13D/A](/filings/0001708269-26-000005.md) | Ownership report, active investor, amended | 0001708269-26-000005 | | 2026-06-11 | 16:42 ET | [8-K](/filings/0001193125-26-267741.md) | 5.07 Shareholder vote results | 0001193125-26-267741 | | 2026-05-19 | 07:00 ET | [8-K](/filings/0001193125-26-229610.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-229610 | | 2026-05-07 | 07:08 ET | [10-Q](/filings/0001193125-26-210303.md) | Quarterly report, period 2026-03-31 | 0001193125-26-210303 | | 2026-05-07 | 07:04 ET | [8-K](/filings/0001193125-26-210291.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-210291 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-104156.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/b3840173-b612-40cc-a2cb-86c76b13bd65) ## About the filer - CIK: 1703647 - Tickers: KRRO - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:32 ET. No prices; not investment advice.